Is there one mandatory baseline panel for every GLP-1 patient?

No universal panel follows from the medication class name alone. The clinician should choose testing based on the product, history and clinical question, rather than treating a commercial wellness bundle as a requirement for everyone. [1, 2]

Can recent results be useful at the first visit?

Bring them, including collection dates and reference ranges. The clinician can decide whether they answer the current question or need updating; having a result is different from knowing that it is relevant to the proposed treatment.

Does a normal panel prove I am eligible for medication?

No. Laboratory values are only part of the assessment. The clinician still considers the product's indication, history, other medicines and label precautions, so normal results do not replace the prescribing decision or establish universal safety. [1, 2]

What should I ask about a test ordered during treatment?

Ask which concern prompted it, when to have it collected and who will explain the result. Product labels identify certain circumstances that need monitoring, but an individual follow-up plan should explain why the test matters in your case. [1, 2]

What labs should you get before starting semaglutide or tirzepatide?

Medical reviewer of record:

Updated 2026-09-16

There is no universal blood panel every person must buy before semaglutide or tirzepatide. A clinician selects tests based on the indication, medical history, symptoms, current medicines, and existing results. An expensive broad panel is not a substitute for that assessment. ^{1, 2, 3}

Glucose or A1C can help assess diabetes status. Kidney function and other tests may be useful depending on the patient and treatment context. Recent valid results may already answer some questions.

Testing does not determine suitability on its own. The assessment also includes contraindications, relevant symptoms, pregnancy considerations, and medication interactions.

Do the drug labels require the same tests for everyone?

No. Label monitoring instructions depend on context. For example, glucose monitoring is relevant for patients with diabetes, and kidney-function assessment can matter when adverse effects cause volume depletion.

Should I request thyroid tumor blood screening?

Routine calcitonin measurement or thyroid ultrasound is not established as useful screening for all patients taking these medicines. A history of medullary thyroid carcinoma or MEN2 is a separate contraindication question for the prescriber.

What should I ask the clinician?

Ask which tests will change the plan, whether existing results are sufficient, and when follow-up testing is needed. Confirm how results and concerning symptoms will be reviewed.

Bottom line

Choose baseline tests to answer specific clinical questions. The right assessment combines history, appropriate tests, and follow-up.

Explore physician-guided lab testing

Frequently asked questions

Your bloodwork, connected to what's next

Your results, explained in plain language
A personalized action plan for what comes next
Direct access to medication when you need it
FSA & HSA eligible with all plans

Learn more about lab testing Get started

From$199/year

Was this helpful?